Brain Injuries

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide

267%

Small Molecule

133%

+ 20 programs with unclassified modality

On Market (2)

Approved therapies currently available

BYETTAApproved

exenatide

AstraZeneca

GLP-1 Receptor Agonist [EPC]subcutaneous2005

21M Part D

EXENATIDE SYNTHETICApproved

exenatide

AstraZeneca

GLP-1 Receptor Agonist [EPC]subcutaneous2024

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

PfizerNEW YORK, NY

2 programs

GenotropinPhase 41 trial

Active Trials

NCT00555009Terminated10Est. Jan 2009

NCT00432263Withdrawn0

MedtronicNJ - Phillipsburg

1 program

ExenatidePhase 4Peptide1 trial

Active Trials

NCT02058940Completed8Est. Aug 2017

AstraZenecaCAMBRIDGE, United Kingdom

1 program

ExenatidePhase 4Peptide

Human BioSciencesWV - Martinsburg

5 programs

magnesium sulfatePhase 31 trial

CDP-CholinePhase 21 trial

AAT - DogN/A1 trial

Animal Assisted TherapyN/A1 trial

Head Impact Recording TechnologyN/A1 trial

Active Trials

NCT04016961Completed4Est. Jul 2021

NCT05250180Recruiting90Est. Jun 2026

NCT00060827Withdrawn0

+2 more trials

Syneos HealthNC - Morrisville

1 program

ProgesteronePhase 31 trial

Active Trials

NCT01143064Completed1,195Est. Mar 2014

Defence TherapeuticsBC - Vancouver

1 program

hypertonic saline mixed with dextranPhase 2/31 trial

Active Trials

NCT00878631Completed113Est. Dec 2008

Neuren PharmaceuticalsAustralia - Camberwell

2 programs

NNZ-2566Phase 21 trial

Active Trials

NCT01366820Completed261Est. Jan 2016

NCT00805818Completed261Est. Jan 2016

BrainScopeMD - Bethesda

3 programs

BrainScope Ahead 200N/A1 trial

BrainScope Ahead 300iP-ON/A1 trial

Active Trials

NCT02367300Completed981Est. Jan 2016

NCT02367274Completed421Est. Apr 2016

NCT04074486Completed1,318Est. Mar 2022

Innovation PharmaceuticalsMA - Wakefield

2 programs

Activity monitor groupN/A1 trial

The rehabilitation gamingN/A1 trial

Active Trials

NCT05571462Unknown100Est. Apr 2024

NCT02425527Completed90Est. Apr 2016

AbbottABBOTT PARK, IL

1 program

Biomarker Testing using the Alinity Whole-blood TBI biomarker i-STATN/ASmall Molecule1 trial

Active Trials

NCT06932588Recruiting350Est. Jun 2026

Oregon TherapeuticsFrance - Paris

1 program

Collaborative Interpersonal Strategy Building with Audio ReflectionN/A1 trial

Active Trials

NCT05603117Completed8Est. Oct 2021

Angeles TherapeuticsCA - Los Angeles

1 program

EV1000 and closed-loop systemN/A1 trial

Active Trials

NCT03991052Completed23Est. Jul 2021

Novo NordiskBAGSVAERD DENMARK, Denmark

1 program

Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal HaemorrhagesN/A1 trial

Active Trials

NCT00435006CompletedEst. Jun 2006

Temple TherapeuticsNetherlands - Geleen

1 program

MATADOC and CRS-RN/A1 trial

Active Trials

NCT02959736Unknown80Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

MedtronicExenatide

PfizerGenotropin

Syneos HealthProgesterone

Human BioSciencesmagnesium sulfate

Defence Therapeuticshypertonic saline mixed with dextran

Neuren PharmaceuticalsNNZ-2566

Human BioSciencesCDP-Choline

AbbottBiomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT

Innovation PharmaceuticalsActivity monitor group

Human BioSciencesAnimal Assisted Therapy

Oregon TherapeuticsCollaborative Interpersonal Strategy Building with Audio Reflection

Angeles TherapeuticsEV1000 and closed-loop system

BrainScopeBrainScope Ahead 300iP-O

Showing 15 of 21 trials with date data

Clinical Trials (22)

Total enrollment: 5,332 patients across 22 trials

NCT02058940 MedtronicExenatide

Intravenous Exenatide in Patients With Acute Brain Injury

Start: Aug 2015Est. completion: Aug 20178 patients

Phase 4Completed

NCT00555009 PfizerGenotropin

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury

Start: Mar 2008Est. completion: Jan 200910 patients

Phase 4Terminated

NCT00432263 PfizerGenotropin

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.

Start: Apr 20070

Phase 4Withdrawn

NCT01143064 Syneos HealthProgesterone

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

Start: Jun 2010Est. completion: Mar 20141,195 patients

Phase 3Completed

NCT00065949 Human BioSciencesmagnesium sulfate

Magnesium Sulfate to Prevent Brain Injury in Premature Infants

Start: Aug 1987Est. completion: Feb 2003

Phase 3Unknown

NCT00878631 Defence Therapeuticshypertonic saline mixed with dextran

Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline

Start: Sep 2004Est. completion: Dec 2008113 patients

Phase 2/3Completed

NCT01366820 Neuren PharmaceuticalsNNZ-2566

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

Start: Feb 2013Est. completion: Jan 2016261 patients

Phase 2Completed

NCT00805818 Neuren PharmaceuticalsNNZ-2566

Study of NNZ-2566 in Patients With Traumatic Brain Injury

Start: Apr 2010Est. completion: Jan 2016261 patients

Phase 2Completed

NCT00727246 Human BioSciencesCDP-Choline

CDP-Choline and Working Memory After TBI: A Neuroimaging Study

Start: Mar 2009Est. completion: May 201319 patients

Phase 2Completed

NCT00060827 Human BioSciencesHead Impact Recording Technology

Measuring Head Impacts in Sports

N/AWithdrawn

NCT06932588 AbbottBiomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT

Biomarker Role in Assessing Imaging Needs for Mild Cranial Trauma

Start: May 2025Est. completion: Jun 2026350 patients

N/ARecruiting

NCT05571462 Innovation PharmaceuticalsActivity monitor group

Mobility and Activity Patterns in Hospitalised Severe Brain Injury

Start: Nov 2022Est. completion: Apr 2024100 patients

N/AUnknown

NCT05250180 Human BioSciencesAnimal Assisted Therapy

Animal Assisted Therapy After Pediatric Brain Injury: Mediators and Moderators of Treatment Response.

Start: Jul 2022Est. completion: Jun 202690 patients

N/ARecruiting

NCT05603117 Oregon TherapeuticsCollaborative Interpersonal Strategy Building with Audio Reflection

CISBAR Intervention for Social Communication After ABI

Start: Apr 2021Est. completion: Oct 20218 patients

N/ACompleted

NCT03991052 Angeles TherapeuticsEV1000 and closed-loop system

Controlled MAP in the Brain Injury Patient (COMAT Study)

Start: Dec 2019Est. completion: Jul 202123 patients

N/ACompleted

NCT04074486 BrainScopeBrainScope Ahead 300iP-O

Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

Start: Oct 2019Est. completion: Mar 20221,318 patients

N/ACompleted

NCT04016961 Human BioSciencesAAT - Dog

Human-Animal Interaction to Promote Recovery Following Pediatric Brain Injury

Start: Aug 2019Est. completion: Jul 20214 patients

N/ACompleted

NCT02959736 Temple TherapeuticsMATADOC and CRS-R

Validating the MATADOC Against Best Practice Standard External Reference Standard

Start: Dec 2016Est. completion: Dec 202080 patients

N/AUnknown

NCT02425527 Innovation PharmaceuticalsThe rehabilitation gaming

Digital Gaming for Persons With Traumatic Brain Injury

Start: Jun 2015Est. completion: Apr 201690 patients

N/ACompleted

NCT02367300 BrainScopeBrainScope Ahead 200

Validation Of TBI Detection System For Head Injured Patients

Start: Feb 2015Est. completion: Jan 2016981 patients

N/ACompleted

NCT02367274 BrainScopeBrainScope Ahead 200

Point-Of-Care TBI Detection System For Head Injured Patients In The Emergency Department

Start: Jan 2015Est. completion: Apr 2016421 patients

N/ACompleted

NCT00435006 Novo NordiskHypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages

Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages

Start: Aug 2003Est. completion: Jun 2006

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 5,332 patients

15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.